Expression of CD44, CD87 and CD123 in Acute Leukemia and Its Correlation with Cellular Immunity / 中国实验血液学杂志

OBJECTIVE@#To investigate the expression of CD44, CD87 and CD123 in acute leukemia and its correlation with cellular immune markers.@*METHODS@#A total of 166 patients with acute leukemia (AL) admitted from May 2014 to February 2017 were enrolled in AL groups. Among these patients, 100 patients suffered from acute myeloid leukemia, 50 patients suffered from acute lymphoid leukemia, and 16 patients showed B/medullary phenotype. At the same time 50 patients with non-acute leukemia were enrolled in the control group. 5 ml of fasting venous blood collected from the patients in each group, and the percentage of CD44, CD87 and CD123 cells was determined by three-color flow cytometry. Symptomatic chemotherapy was given to the patients with confirmed acute leukemia, and the remission was evaluated after 2 treatmen courses. The Complete remission (CR) was recorded and the percentage of CD44, CD87 and CD123 cells under different curative efficacy were recorded. The correlation of the prognosis patients with CD44, CD87 and CD123 was analyzed by SPSS Pearson correlation analysis software.@*RESULTS@#The positive rates of CD44, CD87 and CD123 in AL group were all higher than those in the control group (P＜0. 05). The positive rates of CD44 and CD123 in acute myeloid leukemia group were higher than those in acute lymphoblastic leukemia group and B/myeloid phenotype group (P＜0. 05). The positive rate of CD44 in acute lymphoid leukemia group was higher than that in B/medullary double phenotype group (P＜0.05). The treatment in the patients of AL group was successfully completed. 132 patients reachel to CR and 34 patients to PR+NR after 2 courses. The positive rates of CD44, CD87 and CD123 in CR patients were lower than those in PR+NR patients (P＜0.05). The results of SPSS Pearson correlation analysis showed that the prognosis of patients with acute leukemia negatively correlated with CD44 and CD87 (P＜0.05).@*CONCLUSION@#The expression of CD44, CD87 and CD123 in different phenotype of acute leukemia are different, which correlateds with prognosis. The determination of CD44, CD87 and CD123 can be used to evaluate the prognosis of patients for the reference of clinical treatment.

Expression of CD133-2 during the Courses of Acute Leukemia and Its Clinical Significance / 现代检验医学杂志

Objective To explore the expression of CD133-2 during the treatment course of acute leukemia(AL) and its clinical significance.Methods Used flow cytometry with direct immunofluorescence staining to analyze CD133-2 of 67 acute leukemia patients with different treatment courese.Results The CD133-2 positive rate (52.4％)and expression rate (23.9％±21.5％) in AL were significantly higher than those in control (0,2.2％ ±3.9％).The CD133-2 positive rates of cases for primary treatment group,CR group and recurrence group were 52.4 ％,0 and 40.0 ％ respcctively,and expression rates were 23.9％±21.5％,5.0％±6.0％ and 28.4％±25.6％ respectively.There were significant difference in the positive rate and expression rate of CD133-2 among the three group (x2 =12.777,F=5.906,P＜0.05).The CD133-2 positive rates and expression rates in primary treatment group and recurrence group were significantly higher than those in complete remission cases.CD133-2 positive rate of CD34 + group was obviously higher than that of CD34-group (40.5％ vs 7.1％,x2=8.636,P＜0.05),and the CR rate of CD133-2-/CD34-group was significantly higher than that of CD133-2+/CD34 +group (83.3％ vs 33.3％,x2=6.078,P＜0.05).Conclusion The expression of CD133-2 was correlated with CD34,and CD133/CD34 co-overexpression might be a bad prognostic factor of AL.CD133-2 can be used as one of the indicator of predicting recurrence and monitoring MRD.

Effects of sodium ozagrel in primary thrombocytosis combined with thrombosis / 中国实验血液学杂志

This study was aimed to investigate the incidence of thrombosis in patients with primary thrombocytosis (PT) and its correlation with function changes of platelets, and to explore the effect of thromboxane A2 (TXA2) inhibitor-ozagrel sodium on platelet activity and its efficacy for prevention and treatment of thrombosis. The CD62P and PAC-1 levels on platelet surface were detected by flow cytometry; the levels of TXB2 (metabolic product of TXA2) and 6-keto-PGFIalpha (metabolic product of prostacyclin) were detected by FLISA. The function change of platelets and its correlation with thrombosis were observed and compared in PT patients with and without thrombosis. The results indicated that the TXB2, PAC-1 and CD62P level, and TXB2/6-keto-PGF1alpha ratio in PT patients with thrombosis were higher than those in PT patients without thrombosis before treatment with ozagrel sodium (p<0.01). After treatment with ozagrel sodium, the function indexes of platelets such as CD62P, PAC-1, TXB2 and TXB2/6-keto-PGF1alpha except 6-keto-PGF1alpha in PT patients with and without thrombosis decreased obviously (p<0.01), but there was no significant difference in TXB2, 6-keto-PGF1alpha and TXB2/6-keto-PGF1alpha levels between PT patients with and without thrombosis except CD62P and PAC-1. It is concluded that the multi-index of platelets in PT patients with thrombosis are higher than that in PT patients without thrombosis, the activation of platelet function is a high risk factor for thrombosis of PT patients. The ozagrel sodium can obviously reduce the platelet activation, decrease the production of TXA2 and ameliorate the TXB2/6-keto-PGF1alpha ratio. The ozagrel sodium not only possesses therapeutic effect, but also preventive efficacy for thrombosis.